Lipid Matters

An exciting series of insights and discoveries in lipid science, brought to you by a diverse line-up of contributors! Dive into our blog for fresh takes on ground-breaking publications and thought-provoking items that push the boundaries of lipid research.

9th November 2026

Myriocin: A Decade of Discovery

Sphingolipids (SLs) and ceramides are important lipids that not only play essential structural roles in eukaryotic membranes, but have also been shown to be key players in the mammalian immune system, with SL imbalances linked to many human diseases (e.g. metabolic syndrome, Alzheimer’s). The core, early steps of SL biosynthesis are conserved in all species studied to date (mammals, yeast, bacteria, plants) with the main difference being the locations of the enzymes involved; in the endoplasmic reticulum (ER) for eukaryotes and in the cytoplasm for prokaryotes.

A key tool for studying SL biosynthesis in all species is the natural product myriocin, an unusual lipid known to be produced by the fungal species Isaria sinclarii and Mycelia sterilia. Myriocin (LMSD:LMFA01060203) was isolated in the early 1990s as an antifungal agent, and then re-discovered as ISP-1 with potent immunomodulatory activity. It was explored for potential pharmaceutical applications, but was deemed too toxic for clinical use. Myriocin shares a lot of similar structural features with SLs and so it is not surprising that it acts by inhibiting the first enzyme in the pathway, serine palmitoyltransferase (SPT), that catalyses the reaction between L-serine and fatty acyl-thioester substrates. Recent x-ray and cryo-EM structural studies of both bacterial and mammalian SPT complexes have revealed molecular details of how Nature’s potent agent inhibits all SPTs. Myriocin appears to use its unusual carboxy-containing head group and long C20 fatty acid tail to be an agonist with nM activity. However, the details of how myriocin was produced by fungal species were unknown until a team of UK and international collaborators led by Alex Brand (originally Aberdeen, now Exeter) and Dominic Campopiano (Edinburgh) undertook what turned out to be a ~10 year study.

(https://www.nature.com/articles/s42003-026-10708-9)

We began by using mass spectrometry to show I. sinclairii and M. sterilia produce myriocin under laboratory conditions in a time (0-24 days) and temperature (25/37/45 °C) dependent manner. We then carried out genome sequencing of both fungal producers and used sophisticated annotation techniques to identify the potential biosynthetic gene clusters (BGCs) that could encode the enzymes in the pathway. This was no easy task since the I. sinclairii and M. sterilia genomes, 25.2 Mb and 34.2 Mb, encode 27 and 20 secondary metabolite BGCs, respectively. The annotation was helped by a 2022 study which identified the BGC of sphingofungin, a closely-related “sphingosine-like mycotoxin (SLM)” from the fungus Aspergillus fumigatus. A comparison of the predicted open reading frames (ORFs) from the I. sinclairii and M. sterilia BGCs suggested how the two fungi evolved a convergent evolutionary pathway to make the same molecule. These analyses led our team to carry out a detailed biochemical study of the MyrA enzyme that catalyses the installation of the characteristic carboxy head group of myriocin from an aminomalonate substrate. It also allowed a prediction of how the C20 long fatty acid chain is produced by a large, multi-functional polyketide synthase (PKS)-like enzyme MyrB. Finally, our team used a comprehensive phylogenetic analysis of the putative myriocin BGCs to identify the conservation of the core biosynthetic genes across various fungi. This also revealed for the first time that many more fungal species have the potential to produce myriocin and numerous other SLMs. Overall, this study provided the first genetic and biochemical evidence to support the annotation of the BGC of Nature’s most well-known and useful SL inhibitor. It shows how a combination of experimental techniques (microbiology, genomic analysis, chemistry, enzymology) and scientific expertise are required to define such a complex system. This paper lays the foundation for future studies to investigate the impact of deletion of the putative myriocin BGC, movement of the cluster into alternative hosts and a detailed characterisation of the enzymes involved in the complete myriocin biosynthetic pathway.

Dominic Campopiano

University of Edinburgh

Archive

2026
2025
2024
2023

Go to older Lipid Matters posts Bill Christie's occasional series of notes on publications or other items dealing with lipid science. For the previous curated collection of comments from the world of lipid research please visit - Lipid Trends